CN116802174A - 用于治疗神经系统病症的苏拉明的鼻内施用 - Google Patents

用于治疗神经系统病症的苏拉明的鼻内施用 Download PDF

Info

Publication number
CN116802174A
CN116802174A CN202180085815.2A CN202180085815A CN116802174A CN 116802174 A CN116802174 A CN 116802174A CN 202180085815 A CN202180085815 A CN 202180085815A CN 116802174 A CN116802174 A CN 116802174A
Authority
CN
China
Prior art keywords
suramin
mice
weeks
patient
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180085815.2A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·德比
扎卡里·罗梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parks Medical Co ltd
Original Assignee
Parks Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parks Medical Co ltd filed Critical Parks Medical Co ltd
Publication of CN116802174A publication Critical patent/CN116802174A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180085815.2A 2020-10-22 2021-10-20 用于治疗神经系统病症的苏拉明的鼻内施用 Pending CN116802174A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104350P 2020-10-22 2020-10-22
US63/104,350 2020-10-22
PCT/US2021/055908 WO2022087174A1 (en) 2020-10-22 2021-10-20 Intranasal administration of suramin for treating nervous system disorders

Publications (1)

Publication Number Publication Date
CN116802174A true CN116802174A (zh) 2023-09-22

Family

ID=81289355

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180085815.2A Pending CN116802174A (zh) 2020-10-22 2021-10-20 用于治疗神经系统病症的苏拉明的鼻内施用

Country Status (8)

Country Link
US (1) US20230390226A1 (enExample)
EP (1) EP4229035A4 (enExample)
JP (1) JP2023546923A (enExample)
CN (1) CN116802174A (enExample)
AU (1) AU2021366666A1 (enExample)
CA (1) CA3194818A1 (enExample)
IL (1) IL302223A (enExample)
WO (1) WO2022087174A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11080495B2 (en) * 2018-10-25 2021-08-03 Unified Information Devices, LLC Animal motion and temperature monitoring
CN116867487A (zh) * 2020-07-29 2023-10-10 完美日光有限公司 苏拉明的制造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110494140A (zh) * 2017-02-09 2019-11-22 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
US20200030265A1 (en) * 2017-02-08 2020-01-30 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
CN114340597A (zh) * 2019-06-07 2022-04-12 帕克斯医学有限公司 用于治疗中枢神经系统障碍的组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200030265A1 (en) * 2017-02-08 2020-01-30 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
CN110494140A (zh) * 2017-02-09 2019-11-22 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
CN114340597A (zh) * 2019-06-07 2022-04-12 帕克斯医学有限公司 用于治疗中枢神经系统障碍的组合物和方法

Also Published As

Publication number Publication date
US20230390226A1 (en) 2023-12-07
AU2021366666A1 (en) 2023-06-15
JP2023546923A (ja) 2023-11-08
EP4229035A4 (en) 2024-07-31
CA3194818A1 (en) 2022-04-28
IL302223A (en) 2023-06-01
WO2022087174A1 (en) 2022-04-28
AU2021366666A9 (en) 2024-02-08
EP4229035A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
CN114340597B (zh) 用于治疗中枢神经系统障碍的组合物和方法
ES2891306T3 (es) Combinación de ibudilast y riluzol y métodos de utilización de los mismos
CN116802174A (zh) 用于治疗神经系统病症的苏拉明的鼻内施用
CN116744914A (zh) 用于治疗神经系统病症的抗嘌呤能组合物的施用
CN102143686A (zh) 用4-氨基吡啶持续治疗脱髓鞘病患者
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
HK40073161A (en) Compositions and methods for treating central nervous system disorders
HK40073161B (zh) 用於治疗中枢神经系统障碍的组合物和方法
EP4470563A1 (en) New therapy and prevention for suppressing aging-related disorders including sarcopenia
Hazra A comparative study on the pharmacovigilance scoring of causality assessment grading and staging of topical pharmacotherapy of ofloxacin 0.3% ophthalmic solution in bacterial conjunctivitis and ofloxacin 0.3% otic solution in otitis externa
US20070054940A1 (en) Remedy for down&#39;s syndrome
WO2026052068A1 (zh) 药物组合物的用途
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
HK40102267A (zh) 用於治疗孤独症谱系障碍(asd)的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230922